Stock events for Fortrea Holdings, Inc. (FTRE)
Fortrea's stock has experienced significant volatility, influenced by its financial performance and market sentiment. Key events include the Q4 2025 earnings report, which missed analyst estimates and led to a sharp decline in share price and analyst downgrades. The Q3 2025 earnings report showed better-than-expected revenue but a non-GAAP profit below consensus estimates. Analyst sentiment has been mixed, with a "Hold" consensus and an average price target of $16.75 as of February 25, 2026. The stock has seen significant daily fluctuations.
Demand Seasonality affecting Fortrea Holdings, Inc.’s stock price
Information directly detailing the seasonality of demand for Fortrea's products and services is limited. The clinical research industry can experience seasonal investment needs. The fervor for new drug research has declined compared to the period after COVID, resulting in less money flowing to biotech companies that hire CROs. Fortrea's annualized revenue has declined over the last two to four years, suggesting that demand for its services has consistently shrunk.
Overview of Fortrea Holdings, Inc.’s business
Fortrea Holdings, Inc. is a global contract research organization (CRO) that provides clinical development solutions to the life sciences industry. The company manages all aspects of clinical trials, from Phase I through Phase IV, and offers flexible delivery models. Fortrea focuses on therapeutic areas such as oncology, central nervous system and neurodegenerative diseases, rare diseases, and cell and gene therapies.
FTRE’s Geographic footprint
Fortrea Holdings Inc. is headquartered in Durham, North Carolina, and has operations in approximately 90 to 100 countries worldwide. The company maintains primary office locations in the United States, the United Kingdom, China, India, and Singapore, with field operations in other jurisdictions globally.
FTRE Corporate Image Assessment
Fortrea's brand reputation has been influenced by strategic developments and financial performance. A strategic collaboration with SCTbio aims to accelerate cell and gene therapy development and delivery. Following its spin-off from Labcorp, Fortrea faced an industry slowdown, increased spending, and a significant debt load, leading to earnings turning into losses and a declining stock price.
Ownership
Fortrea Holdings Inc. has a diverse ownership structure, including institutional, retail, and individual investors. As of February 27, 2026, 444 institutional owners and shareholders held a total of 100,430,277 shares, with BlackRock, Inc. being the largest individual institutional shareholder. Approximately 0.53% of the company's stock is owned by insiders.
